Vahedian Zakieh, Fakhraie Ghasem, Faraji Marzye, Tabatabaei Seyed Mehdi
Glaucoma Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Qazvin Square, Tehran, Iran.
Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Int Ophthalmol. 2021 Nov;41(11):3549-3557. doi: 10.1007/s10792-021-01940-9. Epub 2021 Jun 25.
To track changes in the morphology of hyperemic blebs in eyes undergone trabeculectomy with mitomycin C 0.02% (MMC) after triamcinolone acetonide (TA) injection.
A total of 30 eyes of 30 patients with localized or diffuse hyperemia after trabeculectomy with MMC were enrolled in this prospective interventional case series. Two milligrams of TA were injected at the site of maximal injection. Bleb morphology was graded using Indiana Bleb Appearance Grading Scale (IBAGS), and the Moorfields Bleb Grading System (MBGS) 1 week, 1 month, 3 months, 6 months, and 1 year after injection. Failure was defined as intraocular pressure (IOP) more than predefined target IOP for each eye, need for an additional surgical procedure, IOP less than 6 mmHg, and loss of Light Perception (LP) vision.
A total of 27 patients completed a 1-year follow-up period and were included in the final analysis. The mean time interval from trabeculectomy to injection of TA was 5.98 ± 2.57 weeks. The bleb height and vascularity in the IBAGS system decreased significantly after the intervention (p < 0.05), with an increase in bleb extension (p = 0.006). Using MBGS, the bleb area did not change significantly following TA injection (p = 0.056) but its height and vascularity significantly decreased in both central and peripheral areas and the surrounding conjunctiva (p = 0.032). The development of a mature cataract was the only complication that could be attributed to TA injection.
Injection of TA in hyperemic failing blebs improves bleb morphology by decreasing vascularity and height while increasing the extent with an acceptable safety profile.
追踪在注射曲安奈德(TA)后,接受0.02%丝裂霉素C(MMC)小梁切除术的眼睛中充血性滤过泡形态的变化。
本前瞻性干预性病例系列纳入了30例接受MMC小梁切除术后出现局部或弥漫性充血的患者的30只眼睛。在最大充血部位注射2毫克TA。在注射后1周、1个月、3个月、6个月和1年,使用印第安纳滤过泡外观分级量表(IBAGS)和 Moorfields滤过泡分级系统(MBGS)对滤过泡形态进行分级。失败定义为眼压(IOP)高于每只眼睛预先设定的目标眼压、需要额外的手术、眼压低于6 mmHg以及光感(LP)视力丧失。
共有27例患者完成了1年的随访期并纳入最终分析。从小梁切除术到注射TA的平均时间间隔为5.98±2.57周。干预后,IBAGS系统中的滤过泡高度和血管化程度显著降低(p<0.05),滤过泡范围增加(p = 0.006)。使用MBGS,注射TA后滤过泡面积无显著变化(p = 0.056),但其高度和血管化程度在中央和周边区域以及周围结膜均显著降低(p = 0.032)。成熟白内障的发生是唯一可归因于TA注射的并发症。
在充血性失败滤过泡中注射TA可通过降低血管化程度和高度,同时增加范围来改善滤过泡形态,且安全性可接受。